Simcere Pharmaceutical: Marketing application for zeprutinib for the treatment of rheumatoid arthritis accepted by the National Medical Products Administration

Simcere Pharmaceutical announced on November 6 that the New Drug Application for zepuzetinib, a highly selective second-generation JAK1 inhibitor developed in collaboration with Lynk Pharmaceuticals Co., Ltd., for the treatment of moderate-to-severe active rheumatoid arthritis, has been officially accepted by the Center for Drug Evaluation of the National Medical Products Administration. This is also the second indication for zepuzetinib to enter the regulatory review stage in China.